#1 Clinical Trials Search in Europe

Fipaxalparant

Fipaxalparant, also known as HZN-825, is an investigational drug currently being studied in clinical trials for the treatment of diffuse cutaneous systemic sclerosis and idiopathic pulmonary fibrosis. These trials aim to evaluate the efficacy, safety, and tolerability of Fipaxalparant in patients with these challenging conditions. The studies involve different dosing regimens and compare the drug’s effects to placebo, focusing on improvements in lung function, skin involvement, and overall quality of life for patients.

Table of Contents

What is Fipaxalparant?

Fipaxalparant, also known as HZN-825, SAR100842, or SAR-100842, is an investigational medication being developed by Horizon Therapeutics Ireland DAC[1]. It is a tablet form of medicine that is taken orally and is currently being studied for its potential benefits in treating certain rare and serious medical conditions[2].

Conditions Treated

Fipaxalparant is being investigated for the treatment of two main conditions:

  1. Diffuse Cutaneous Systemic Sclerosis (dcSSc): This is a rare autoimmune disease that causes hardening and tightening of the skin and can also affect internal organs[1].
  2. Idiopathic Pulmonary Fibrosis (IPF): This is a chronic lung disease characterized by scarring (fibrosis) of the lungs, which makes breathing difficult[3].

How It Works

Fipaxalparant is a selective antagonist of LPAR1 (Lysophosphatidic Acid Receptor 1)[2]. This means it blocks the action of a specific receptor in the body that is involved in processes like inflammation and fibrosis (scarring). By targeting this receptor, Fipaxalparant aims to reduce the progression of diseases characterized by excessive scarring and inflammation.

Clinical Trials

Fipaxalparant is currently being studied in several clinical trials:

  1. For Diffuse Cutaneous Systemic Sclerosis (dcSSc):
    • A 52-week study (HZNP-HZN-825-301) comparing two different doses of Fipaxalparant to a placebo in patients with dcSSc[1].
    • An open-label extension study (HZNP-HZN-825-302) for patients who completed the first study, allowing them to continue treatment for another 52 weeks[2].
  2. For Idiopathic Pulmonary Fibrosis (IPF):
    • A 52-week study (HZNP-HZN-825-303) comparing two different doses of Fipaxalparant to a placebo in patients with IPF, followed by an optional 52-week extension phase[3].

Dosage and Administration

In the clinical trials, Fipaxalparant is being tested at different dosages:

  • 300 mg once daily (QD)
  • 300 mg twice daily (BID)

The medication is taken orally in tablet form, usually with meals[1][2][3].

Potential Benefits

The clinical trials are evaluating several potential benefits of Fipaxalparant, including:

  • For dcSSc:
    • Improvement in lung function (measured by forced vital capacity or FVC)[1]
    • Reduction in skin thickening (measured by the modified Rodnan skin score or mRSS)[1]
    • Improvement in overall disease status and quality of life[1][2]
  • For IPF:
    • Slowing the decline in lung function (measured by FVC)[3]
    • Improvement in exercise capacity (measured by the 6-minute walk test)[3]
    • Better quality of life and reduced symptoms[3]

Safety and Side Effects

As Fipaxalparant is still in clinical trials, its full safety profile is not yet established. The ongoing studies are closely monitoring for any adverse events (side effects)[1][2][3]. Some areas of particular interest include:

  • Cardiovascular effects
  • Effects on blood pressure
  • Potential interactions with other medications

It’s important to note that all participants in these trials are carefully screened and monitored throughout the study period to ensure their safety[1][2][3].

Conclusion

Fipaxalparant (HZN-825) is a promising investigational medication for the treatment of diffuse cutaneous systemic sclerosis and idiopathic pulmonary fibrosis. While it shows potential in addressing these challenging conditions, it’s important to remember that the drug is still in the testing phase. The ongoing clinical trials will provide more information about its effectiveness and safety. Patients interested in this treatment should discuss it with their healthcare providers and consider participating in clinical trials if appropriate.

Aspect Details
Drug Name Fipaxalparant (HZN-825)
Conditions Studied Diffuse Cutaneous Systemic Sclerosis, Idiopathic Pulmonary Fibrosis
Trial Phases Phase 2b, Phase 3
Trial Designs Randomized, Double-blind, Placebo-controlled, Open-label Extension
Primary Endpoints Change in FVC % predicted, Skin thickness (mRSS)
Secondary Endpoints Quality of life measures, Disability assessments, Safety and tolerability
Dosing Regimens 300 mg QD, 300 mg BID
Treatment Duration 52 weeks (core phase), up to 104 weeks (with extension)
Key Inclusion Criteria Confirmed diagnosis, Specific lung function parameters, Age ≥18 years
Safety Monitoring Adverse events, Vital signs, ECG, Laboratory evaluations

FAQ

  • What is Fipaxalparant and what conditions is it being studied for? Fipaxalparant, also known as HZN-825, is an investigational drug being studied for the treatment of diffuse cutaneous systemic sclerosis and idiopathic pulmonary fibrosis. It is a selective antagonist of LPAR1, which is believed to play a role in these conditions.
  • How is Fipaxalparant administered in the clinical trials? In the clinical trials, Fipaxalparant is administered orally in tablet form. Different dosing regimens are being studied, including 300 mg once daily (QD) and 300 mg twice daily (BID).
  • What are the main objectives of the Fipaxalparant clinical trials? The main objectives of the trials are to evaluate the efficacy, safety, and tolerability of Fipaxalparant compared to placebo. The studies focus on measuring changes in lung function (FVC % predicted), skin involvement (mRSS), and various patient-reported outcomes.
  • How long do the Fipaxalparant clinical trials last? The core phases of the clinical trials typically last 52 weeks (1 year). Some trials also include extension phases that allow participants to continue treatment for an additional 52 weeks, totaling up to 104 weeks (2 years) of treatment.
  • What are some of the key inclusion criteria for participating in these trials? Key inclusion criteria vary by trial but generally include a confirmed diagnosis of the condition being studied (either diffuse cutaneous systemic sclerosis or idiopathic pulmonary fibrosis), specific lung function parameters, and age requirements. Participants must also be willing to comply with the trial protocol and evaluations throughout the study duration.

Ongoing Clinical Trials on Fipaxalparant

  • Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

    Not recruiting

    1 1
    Investigated drugs:
    Austria France Germany Greece Italy Poland +3

  • Study on Fipaxalparant for Patients with Idiopathic Pulmonary Fibrosis

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    France Greece Italy The Netherlands Poland Spain

  • Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

    Not recruiting

    1
    Investigated drugs:
    Austria France Germany Greece Italy Poland +3

Glossary

  • Diffuse Cutaneous Systemic Sclerosis (dcSSc): A subtype of systemic sclerosis characterized by widespread skin thickening and potential internal organ involvement.
  • Idiopathic Pulmonary Fibrosis (IPF): A chronic, progressive lung disease characterized by scarring (fibrosis) of the lungs, leading to breathing difficulties.
  • Forced Vital Capacity (FVC): The total amount of air exhaled during a forced breath, used to assess lung function.
  • Modified Rodnan Skin Score (mRSS): A clinical assessment tool used to measure skin thickness and involvement in systemic sclerosis.
  • Health Assessment Questionnaire-Disability Index (HAQ-DI): A patient-reported outcome measure assessing functional ability and disability.
  • Physician Global Assessment (MDGA): A tool used by doctors to evaluate the overall disease activity or severity.
  • Patient Global Assessment (PTGA): A measure where patients rate their own perception of their disease activity or health status.
  • LPAR1: Lysophosphatidic Acid Receptor 1, a target of Fipaxalparant believed to be involved in fibrosis.
  • Placebo: An inactive substance used as a control in clinical trials to compare against the effects of the investigational drug.
  • Open-label Extension (OLE): A phase of a clinical trial where all participants receive the active drug, often following a placebo-controlled phase.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-fipaxalparant-in-patients-with-diffuse-cutaneous-systemic-sclerosis-2/
  2. http://clinicaltrials.eu/trial/study-on-the-effects-of-fipaxalparant-in-patients-with-diffuse-cutaneous-systemic-sclerosis/
  3. http://clinicaltrials.eu/trial/56472/